Findings

What do systematic reviews say?

2,908 questions · 3,101 findings · 509 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 571 · 18.4%GRADE not reported 358 · 11.5%Very low 723 · 23.3%Low 854 · 27.5%Moderate 489 · 15.8%High 106 · 3.4%

Intervention not reported

Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

The review found no eligible studies for this question.

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 431 participants
Very low

Intervention not reported

Number of participants with any bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

The intervention showed no clear difference in number of participants with any bleeding (0 to 3 months) (low certainty).

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
RR 0.91 [0.78, 1.06]
3 studies · 448 participants
Low

Intervention not reported

Number of participants with clinically significant bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

The intervention showed no clear difference in number of participants with clinically significant bleeding (0 to 3… (low certainty).

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
RR 0.94 [0.74, 1.19]
4 studies · 511 participants
Low

Intervention not reported

Serious infections (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

The intervention showed no clear difference in serious infections (0 to 3 months) (low certainty).

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
RR 1.2 [0.93, 1.55]
3 studies · 451 participants
Low

Intervention not reported

Length of hospital admission (days) (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 388 participants
Moderate

Intervention not reported

Hospital readmission (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

The intervention showed no clear difference in hospital readmission (0 to 3 months) (low certainty).

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
RR 0.89 [0.52, 1.5]
1 study · 299 participants
Low

Intervention not reported

All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 84 participants
Very low

Intervention not reported

Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

The review found no eligible studies for this question.

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

First‐line thiazides vs beta‐blocker

Total mortality Duration: 1 to 5.8 years · patients with hypertension

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 18241 participants
Moderate

First‐line thiazides vs calcium channel blockers

Cardiovascular events · patients with hypertension

First‐line thiazides probably leads to lower total cardiovascular events Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 0.93 [0.89, 0.98]
6 studies · 35217 participants
Moderate

First‐line thiazides vs calcium channel blockers

Stroke · patients with hypertension

First‐line thiazides showed no clear difference in total stroke Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 1.06 [0.95, 1.18]
6 studies · 35217 participants
Moderate

First‐line thiazides vs calcium channel blockers

Total CHD Duration: 1 to 5 years · patients with hypertension

First‐line thiazides showed no clear difference in total CHD Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 1 [0.93, 1.08]
6 studies · 35217 participants
Moderate

First‐line thiazides vs calcium channel blockers

Congestive heart failure · patients with hypertension

First‐line thiazides probably leads to lower total congestive heart failure Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 0.74 [0.66, 0.82]
6 studies · 35217 participants
Moderate

First‐line thiazides vs calcium channel blockers

Adverse effects (side effects; treatment withdrawals) · patients with hypertension

First‐line thiazides may leads to lower withdrawals due to adverse effects Duration: 1 to 5 years compared with first‐line calcium channel blockers (low certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 0.81 [0.75, 0.88]
7 studies · 33908 participants
Low

First‐line thiazides vs ACE inhibitor

Total mortality Duration: 1 to 5 years · patients with hypertension

First‐line thiazides showed no clear difference in total mortality Duration: 1 to 5 years compared with first‐line ACE inhibitors (moderate certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 1 [0.95, 1.07]
3 studies · 30961 participants
Moderate

First‐line thiazides vs ACE inhibitor

Total serious adverse events · patients with hypertension

The review found no eligible studies for this question.

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

First‐line thiazides vs ACE inhibitor

Cardiovascular events · patients with hypertension

First‐line thiazides showed no clear difference in total cardiovascular events Duration: 2.6 to 5 years compared with first‐line ACE inhibitors (low certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 0.97 [0.92, 1.02]
3 studies · 30900 participants
Low

First‐line thiazides vs ACE inhibitor

Stroke · patients with hypertension

First‐line thiazides probably leads to lower total stroke Duration: 2.6 to 5 years compared with first‐line ACE inhibitors (moderate certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 0.89 [0.8, 0.99]
3 studies · 30900 participants
Moderate

First‐line thiazides vs ACE inhibitor

Total CHD Duration: 2.6 to 5 years · patients with hypertension

First‐line thiazides showed no clear difference in total CHD Duration: 2.6 to 5 years compared with first‐line ACE inhibitors (moderate certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 1.03 [0.96, 1.12]
3 studies · 30900 participants
Moderate